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Liver diseases are becoming increasingly prominent in
HIV-infected patients. These diseases are among the lead-
ing causes of non AIDS-associated deaths. The develop-
ment of liver fibrosis represents the most clinically relevant
and common pathway of hepatic injury, and early recogni-
tion of liver fibrosis is an essential component of its diag-
nostics and therapy (Kaspar and Sterling, 2017).
Liver biopsy remains the gold standard for the assessment
of liver fibrosis. However, the use of biopsy is limited by
possible complications associated with its invasive nature,
heterogeneity of the liver, and some level of subjectivity in
conclusions (Bravo et al., 2001). Therefore, this method is
not available for massive screening of the disease. Non-
invasive methods involve transient elastography (a method
of measuring the mean stiffness of hepatic tissue) and inves-
tigation of blood serum. Taking into account a relatively
high variability in the rate of progression of liver fibrosis
(Konerman et al., 2014), biomarkers represent essential
tools for the assessment of the disease by using a simple
blood test (Neuman et al., 2016).
Biomarkers of liver fibrosis can be divided into two groups
(Schmid et al., 2015). The first group includes direct mark-
ers of liver fibrosis and markers of hepatic metabolisms
(e.g., hyaluronic acid, matrix metalloproteinases, and tissue
inhibitor of matrix metalloproteinase). The second group
consists of indirect biochemical markers of liver functioning
(e.g., alanine aminotransferase, aspartate aminotransferase,
and bilirubin). In addition, some indexes (e.g., APRI,
FIB-4, Forns index) are used for a complex assessment of
the fibrosis. All markers are suggested for the assessment of
liver fibrosis in patients with HIV and viral hepatitis C
(HCV) coinfection (Peters et al., 2011, Konerman et al.,
2014; Schmid et al., 2015). However, the results of the pre-
vious studies opened inconsistent tendencies in the level of
differentiation of patients with and without HCV coinfec-
tion (Larrousse et al., 2007; Schmid et al., 2015).
Observed inconsistency can be associated with the multifac-
torial determination of liver fibrosis in HIV patients. For ex-
ample, absence or interruption of antiretroviral therapy
(ART) is among the factors leading to progressing liver fi-
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The aim of this study was to assess the main effects and interaction between viral hepatitis C
(HCV) coinfection and antiretroviral therapy (ART) by using a nonparametric ANOVA on direct
and indirect markers of liver fibrosis in HIV-infected patients. The sample included 178 HIV pa-
tients aged from 23 to 65 (36% females). The following parameters were determined in blood of
patients: hyaluronic acid, pro-matrix metalloproteinase-1, alanine aminotransferase, aspartate
aminotransferase, and platelet count. The FIB-4 index was also calculated. The nonparametric
ANOVA revealed no significant interaction between HCV coinfection and ART. This provides evi-
dence for an independent contribution of each factor on promotion of the pathology. The results
also demonstrated that the direct and indirect indicators of liver fibrosis are associated differently
with the studied factors. Therefore, a combination of markers should be used for monitoring of
liver fibrosis in HIV-infected patients.
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brosis in patients with HCV coinfection (Qurishi et al.,
2003; Peters et al., 2011, Kim et al., 2016). At the same
time, multifactorial analysis of markers of liver fibrosis has
been limited by less developed statistical tools for non-
normally distributed variables. Recent developments in the
field of nonparametric analysis opened an opportunity to as-
sess the main effects and interactions of multiple factors
through a nonparametric multiway ANOVA (Hettman-
sperger and McKean, 2011; Kloke and McKean, 2012). The
aim of this study was to assess the main effects and interac-
tion between HCV coinfection and ART by using a non-
parametric ANOVA on direct and indirect markers of liver
fibrosis in HIV-infected patients.
The study was conducted in the Rîga Eastern Clinical Uni-
versity Hospital from 2015 to 2018. The study was ap-
proved by the Ethics Committee of Rîga Stradiòð University
and Ethics Committee of Rîga Eastern Clinical University
Hospital. The inclusion criteria were: age  18, confirmed
HIV monoinfection, and confirmed HIV infection with
HCV coinfection. The exclusion criteria were: alcoholic
liver diseases, opportunistic infection, viral hepatitis B, and
liver cirrhosis or neoplasia.
The diagnosis of HIV was based on detection of positive
HIV1/2 antibody by the 4th generation of ELISA, confirmed
by Western Blot, and on detection of HIV RNS by real-time
polymerase chain reaction (COBAS AmpliPrep/COBAS
TaqMan HIV-1 Test 2.0, Roche, USA, the lower limit of
detection was 20 copies/ml). The HCV coinfection was con-
firmed by detection of HCV antibody (ELISA, Bio-Rad,
France or Ortho-Clinical Diagnostics Inc., USA) and by de-
tection of HCV RNS (COBAS AmpliPrep/COBAS TaqMan
HCV test, Roche, USA) or HCV Core Ag (ELISA Architec
system HCV Ag, Abbot, USA) in plasma.
The study sample included 178 HIV patients aged from 23
to 65 (mean age was 38.48 ± 9.87, 36% females). The me-
dian level of CD4 cell count in the sample was 333 cells/µl,
and interquartile range (IQR) was 193–467 cells/µl. The
median viral load was 366 copies/ml (ranged 0–30300 cop-
ies/ml). The patients formed four groups according to HCV
coinfection and ART status. The group with HCV coinfec-
tion involved 33 HIV patients without ART and 42 patients
with ART. The group without HCV included 49 patients
without ART and 54 patients with ART. Patients received
ART according to the clinical guidelines for diagnosis,
treatment, and prevention of HIV infection: two nucleoside
reverse transcriptase inhibitors (NRTI) combined with one
protease inhibitor (PI) or one non-nucleoside reverse tran-
scriptase inhibitor (NNRTI).
The following parameters were determined in patient
plasma: hyaluronic acid (HA), pro-matrix metalloprotein-
ase-1 (pro-MMP-1), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and platelet count by us-
ing validated methods. FIB-4 index, described by Sterling et
al. (2006), was calculated as FIB-4 = (age × AST) / (plate-
lets (109/L) × ALT1/2).
Statistical analysis was performed with IBM SPSS for Win-
dows 22.0 and R-package ‘Rfit’ 0.23.0, developed by Kloke
and McKean (Kloke and McKean, 2012) as an implementa-
tion of the nonparametric approach to the multi-way analy-
sis of variance with Type III sum of squares (Hettman-
sperger and McKean, 2011).
The Kolmogorov-Smirnov test (ranged from 0.19 to 0.35)
and Shapiro-Wilk test (from 0.39 to 0.82) indicated non-
normal distribution of selected markers. Therefore, a non-
parametric approach to the between-subjects analysis of
variance was applied. Table 1 presents descriptive statistics
for the markers in HIV patients and the results of the two-
way 2 (HCV) × 2 (ART) rank-based ANOVA.
Direct indicators of liver fibrosis demonstrated different
trends. Pro-MMP-1 was significantly higher in HIV patients
with ART without an association with HCV. The level of
hyaluronic acid was higher in HIV patients without HCV
independently of ART. Indirect indicators of fibrosis, ALT
and AST, were higher in HIV patients with HCV than in
those without HCV. ALT was also higher in HIV patients
without ART. Similarly, the FIB-4 index of liver fibrosis
was higher in HIV patients with HCV and in patients with-
out ART. No one interaction of factors was statistically sig-
nificant, which indicated an independent contribution of
HCV coinfection and ART to liver fibrosis.
The results confirmed the negative effects of HCV coinfec-
tion and an absence of ART on liver fibrosis (Qurishi et al.,
2003; Peters et al., 2011, Kim et al., 2016). The direct and
indirect indicators of liver fibrosis related differently to fac-
tors promoting the pathology. Hyaluronic acid and AST
were associated with HCV coinfection. Pro-MMP-1 was as-
sociated with ART only, while ALT and FIB-4 demon-
strated an association with both factors under analysis. The
last finding is in accordance with the suggestion of using
liver fibrosis indexes for indirect assessment (Schmid et al.,
2015).
In summary, a nonparametric two-way ANOVA demon-
strated usefulness for the assessment of the main effects and
the interaction between HCV coinfection and ART in HIV
patients. It can be concluded that there is no universal blood
marker of liver fibrosis. A complex set of direct and indirect
markers should be used in practice. As a result, indexes of
liver fibrosis and particular markers can be analysed.
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T a b l e 1
DESCRIPTIVE STATISTICS AND 2 (HCV) × 2 (ART) RANKED-BASED ANOVA ON MARKERS OF LIVER FIBROSIS IN HIV PATIENTS
Group pro-MMP-1 (ng/ml) HA (µg/ml) ALT (U/L) AST (U/L) FIB-4 Index

























































































Source of variance F F F F F
HCV 0.45 12.97*** 48.70*** 32.54*** 5.21*
ART 8.96** 0.11 4.40* 0.20 6.78*
HCV × ART 0.29 0.62 1.29 0.26 0.79
HA, hyaluronic acid; pro-MMP-1, pro- matrix metalloproteinase-1; ALA, alanine aminotransferase; AST, aspartate aminotransferase; ART, antiretroviral
therapy; HCV, viral hepatitis C; Mdn, median; IQR, interquartile range; ALT, alanine aminotransferase.
* p < 0.05. ** p < 0.01. *** p < 0.001.
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AKNU FIBROZES NEINVAZÎVO MARÍIERU SAISTÎBA AR HCV KOINFEKCIJU UN ANTIRETROVIRÂLO TERAPIJU
PACIENTIEM AR HIV
Pçtîjuma mçríis bija novçrtçt HCV koinfekcijas un antiretrovirâlas terapijas (ART) mijiedarbîbu un galvenos efektus uz tieðajiem un
netieðajiem aknu fibrozes asins maríieriem. Izlasi veidoja 178 pacienti ar HIV infekciju vecumâ no 23 lîdz 65 gadiem (36% bija sievietes).
Pacientu asinîs bija noteikti sekojoði parametri: hialuronskâbe, pro-matrices metâlproteinâze-1, alanînaminotransferâze, aspartâtamin-
otransferâze un trombocîtu skaits. Papildus bija aprçíinâts FIB-4 indekss. Neparametriskâ dispersijas analîze neatklâja nozîmîgu HCV
koinfekcijas un ART mijiedarbîbu. Tas apliecina katra faktora neatkarîgu pienesumu patoloìijas attîstîbâ. Rezultâti parâdîja arî, ka aknu
fibrozes tieðie un netieðie râdîtâji ir daþâdi saistîti ar faktoriem, kuri pastiprina patoloìiju. Tâdçjâdi HIV pacientu aknu fibrozes
monitoringam bûtu jâizmanto maríieru kombinâcija.
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